Purpose: To determine whether tumor grade, molecular subtype and hypoxia predict response to hypofractionated versus standard radiotherapy (RT) following breast-conserving surgery (BCS) for node-negative breast cancer in a randomized controlled trial (RCT).
background
Tumor biomarkers can be prognostic or predictive. The former describe the natural history of a cancer whereas the latter differentiates between tumors that will respond (or not) to a given treatment. In breast cancers, many different biomarkers have been evaluated for their ability to predict response to hormonal therapy and different types of chemotherapy [1] [2] [3] . The experimental design best suited to identify predictive factors is a randomized controlled trial (RCT) where eligible patients are defined, then randomly assigned to one or more treatments and followed prospectively with careful documentation of clinical outcomes.
Biomarkers that predict response to radiotherapy (RT) or different radiation fractionations in patients with breast cancer are less well studied. We have previously conducted a RCT evaluating whether a 3-week schedule of hypofractionated whole-breast RT was as effective as a 5-week standard RT schedule in women with lymph node-negative breast cancer who had undergone breast-conserving surgery (BCS). This study showed that the risk of local recurrence (LR) at 10 years was equivalent in both treatment groups [4] . However, an unplanned subgroup analysis in this trial suggested that the hypofractionated regimen was less effective in patients with high-grade tumors, and that the cumulative incidence of LR at 10 years for patients with high-grade tumors was 4.7% when treated with standard RT when compared with 15 .6% in the hypofractionated RT group. Subsequent to this, the American Society for Radiation Oncology (ASTR0) guidelines for whole-breast irradiation after BCS suggested that hypofractionated RT may not always be advisable in the setting of high-grade disease [5] .
The grading system applied to the tumors in the trial was the Scharff Bloom Richardson (SBR) grading system [6] . This system has subsequently been modified and replaced by the more quantitative and reproducible Nottingham grading system (NGS) which has been demonstrated to be prognostic for LR following BCS and whole-breast RT [7] .
More recently, gene expression profiling experiments have defined new prognostic subsets of breast cancers; luminal A, luminal B, HER2 enriched and basal-like [8] . The primary aim of the current study was to investigate whether tumor grade as determined by the NGS and molecular subtype predicts for a differential response to hypofractionated RT.
The biological effects of radiation are enhanced by oxygen and it has been hypothesized that accelerated schedules such as hypofractionated RT, may be less effective for hypoxic tumors [9] . As a secondary hypothesis, we evaluated the ability of markers of tumor hypoxia to predict response to hypofractionated RT.
methods patients and trial design
Details of study design have been previously reported [4] . Participants had invasive breast cancer treated by BCS and axillary dissection with clear margins of excision and negative axillary nodes. Tumors >5 cm were excluded. Patients were accrued from nine regional cancer centers in Ontario between the years 1993 and 1996. Patients were randomly assigned to receive standard whole-breast RT with a dose of 50 Gy in 25 fractions over a period of 35 days or hypofractionated RT at a dose of 42.5 Gy in 16 fractions over a period of 22 days to the whole breast.
After completion of RT, patients were seen every 6 months for 5 years and then yearly. The primary outcome was any LR of invasive cancer in the treated breast. Secondary outcomes included distant recurrence and overall survival (OS).
specimen collection, centralized pathology review and immunohistochemistry
Of the 1234 women enrolled in the trial, FFPE blocks were received on 989 cases (80.1%) (supplementary material S1, available at Annals of Oncology online, CONSORT diagram). A 4 µm section was cut from the tumor block received, stained with hematoxylin and eosin (H&E), and graded centrally by the study pathologist (AB) using the NGS [9] .
Immunohistochemistry (IHC) for ER, PR, HER2, CK5, EGFR, Ki67, HIF1α, CAIX and GLUT1 was carried out on tissue microarray (TMA) sections using methods as listed in supplementary material S2, available at Annals of Oncology online. The results were assessed by one pathologist (AB) blinded to clinical outcome. TMA construction details, methods of scoring and cut points applied for each antibody, and methods of tumor classification as luminal A, luminal B, HER2 enriched, basal-like or 'unclassified' are detailed in the supplementary material, available at Annals of Oncology online. Tumors were considered hypoxic if they were positive for any of the hypoxia markers (HIF1α, CAIX and GLUT1) examined.
statistical analysis
Demographics for patients with evaluable tumors for this analysis were compared with those whose tumors were not evaluable. Summary statistics were used to describe the patient and tumor characteristics, by subtype. Association between subtypes and patient and pathologic characteristics were carried out using the χ 2 test or stratified log-rank test. Agreement between the NGS and the SBR grades was calculated using a weighted κ.
Outcomes of interest were estimated using the Kaplan-Meier method, and included LR, disease-free survival (DFS) and OS, as defined in the supplementary material, available at Annals of Oncology online. Molecular subtype and hypoxic markers were investigated for their prognostic ability on outcomes using Cox proportional hazards regression models adjusting for a priori selected covariates tumor grade, trial stratum (age, tumor size and adjuvant therapy) and RT received. Predictive utility of tumor grade, molecular subtype and hypoxia markers for RT fractionation schedule was assessed by including their interaction terms in the model. All tests and confidence intervals were two-sided and a P-value of ≤0.05 was considered statistically significant. All statistical analyses were carried out in SAS 9.2 (Cary, NC) and R 2.15 (www.r-project.org).
results
The outcome data reported are based on the dataset from the HWBI trial which was analyzed with a median follow-up of 12 years [4] . The 989 patients with evaluable tumors were compared with the 245 patients without evaluable tumors (Table 1) . Patients with evaluable tumors were similar to those patients without evaluable tumors with the exception that they were more likely to be larger in size (P = 0.06), have a higher tumor grade (P = 0.008) and have received adjuvant systemic therapy (tamoxifen and/or chemotherapy: P < 0.001). Outcomes at 10 years for LR, DFS and OS were similar between patients with evaluable tumors and those without.
From the set of 989 tumors, 975 (98.6%) underwent central (Nottingham) grading. The correlation between central (Nottingham) and SBR (local) grading was moderate with a weighted κ of 0.48. Eight hundred and ninety-four (90.4%) tumors could be classified into one of the four molecular subtypes described; luminal A, luminal B, HER2 enriched or basallike. Ninety-five cases could not be classified into one of the molecular subtypes due to unavailable IHC data and were placed into an 'unclassified' category for purposes of analysis.
The majority of tumors were luminal A (N = 461, 46.6%), followed by luminal B (N = 269, 27.2%), basal-like (N = 125, 12.6%), HER2 enriched (N = 39, 3.9%) and unclassified (N = 95, 9.6%). The clinical-pathologic features are listed in Table 2 . There were significant differences in median patient age, tumor size and grade between subtypes. Patients also varied according to adjuvant systemic therapy received.
prognosis
In the final cohort of 989 patients, 63 had a LR. Statistically significant differences in outcomes were observed between patients from the different molecular subgroups (Table 2) . With respect to the LR, patients with luminal A and basal-like tumors had the most favorable prognosis with 95.5% LR-free survival at 10 years, and those with luminal B and HER2-enriched tumors had the lowest rate at 92.1% and 83.1%, respectively, P < 0.001 ( Figure 1 ). Differences in DFS and OS are reported in the supplementary material, available at Annals of Oncology online. In the multivariable Cox model, only molecular subtype was significantly prognostic for LR, with the HER2 enriched subtype having the worst outcome (Table 3) . Hypoxia markers, HIF1α, CAIX and GLUT1 were all associated with adverse tumor pathological features such as high tumor grade, ER negativity and basal-like molecular subtype (Table 2 ). However, none of them were associated with LR, either alone or in combination (data not shown). After adjusting for treatment, molecular subtype and stratification factors, the hazard ratios [95% confidence interval (CI), P-value] were 1.53 (95% CI 0.84-2.77, P-value = 0.16), 0.84 (95% CI 0.48-1.47, P-value = 0.54) and 0.74 (95% CI 0.41-1.33, P-value = 0.32) for HIF-1α, CA-IX and GLUT1, respectively.
predictive ability
We attempted to replicate the findings of the original analysis that showed an interaction between hypofractionated RT and high-grade using the SBR grade carried out locally for LR in this reduced dataset of 989 patients. Although the trend was in the same direction, the interaction term did not reach statistical significance (P = 0.11), likely due to the smaller sample size. While Nottingham grade carried out centrally had moderate agreement with the SBR grade (weighted κ of 0.48), there was no interaction with type of RT received (hypofractionated or standard) for LR, P = 0.41 (Figure 2) .
No evidence of an interaction between RT fractionation (hypofractionated or standard) and molecular subtype was There was some evidence of an interaction, albeit not statistically significant, between standard RT and the expression of HIF1α observed for LR (Figure 2 ). Tumors that were positive for HIF1α expression had a treatment effect HR of 1.13 (95% CI 0.51-2.53) favoring the standard RT regimen, whereas for those tumors negative for HIF1α (nonhypoxic) the HR was 0.47 (95% CI 0.20-1.09) favoring the 42.5 Gy regimen, the interaction term was P = 0.14. No evidence of an interaction between RT and the expression of the other markers of hypoxia examined (CAIX or GLUT1), either individually or combined with HIF1α (P = 0.58) was observed for LR ( Figure 2) .
discussion
In the original study, an unplanned subgroup analysis suggested that the hypofractionated RT regimen was less effective in patients with high-grade tumors [4] . This observation was unexpected and appeared to contradict the experimental evidence that tumors with a high proliferative rate (high-grade) may be more sensitive to accelerated schedules of radiation therapy. The grading system employed for the original analysis was the SBR system [6] . This system is no longer employed in the grading of breast cancers and has been replaced by the more reproducible and objective NGS which has repeatedly been demonstrated to be prognostic for LR, OS and DFS [8] [9] [10] . The NGS applied by the study pathologist (AB), an expert breast pathologist, correlated modestly with the local hospital SBR grade (κ = 0.48) and was prognostic for outcome; however, it was not shown to be predictive of a response to hypofractionation. The inability of the NGS (or the SBR system) to predict response to hypofractionated RT in this current analysis may be the result of the smaller sample size, or more likely, that the statistically significant result observed in the original study was a chance finding and not a real effect. This result is in keeping with a recent analysis of the UK START A and B trials reporting that tumor grade was not predictive of response to RT fraction size [11] . We further explored the prognostic and predictive value of molecular subtype in this clinical trial setting. Using a sixbiomarker panel, we found that molecular subtype was prognostic of LR on multivariate analysis, out-performing other clinical-pathologic parameters such as patient age, tumor size, grade and use of adjuvant systemic therapy. A number of other studies have shown the ability of molecular subtype to independently predict LR following BCS and RT [12] [13] [14] . In all studies, luminal A-type tumors had a low rate of LR and HER2-enriched tumors have a higher rate of LR. A unique finding of our study was the low rate of LR experienced by patients with basal-like breast cancer. A factor that may have contributed to the low rate of LR in basal-like cancers in this trial is that 51% of patients with this tumor type received systemic cyclophosphamide, methotrexate and fluorouracil (CMF). This regimen has been shown to be more effective than anthracycline containing regimens in reducing both local and distant recurrence in such cancers [15] . Alternatively, our findings could be interpreted to suggest that basal-like breast cancers are relatively radiosensitive possibly due to their known association with DNA repair deficiency [16] and that selected patients with this tumor type may therefore be good candidates for BCS and whole-breast RT [17] . We were not able to demonstrate an interaction between tumor molecular subtype and hypofractionated RT, suggesting that response to RT fraction size is not affected by molecular subtype.
We also explored the potential association between response to hypofractionated RT and tumor hypoxia. We assessed hypoxia by measuring three proteins known to be expressed under hypoxic conditions; HIF1α which is the central regulator of the cellular response to hypoxia and CAIX and GLUT1, both of which are known to be expressed downstream of a functional HIF1α pathway [18] . In this study, all three hypoxia markers were associated with poor prognostic features, as reported elsewhere, but they were not associated with a statistically significant increased incidence of LR nor where they predictive of response to RT fractionation size. Tumor hypoxia is both heterogenous within a tumor and difficult to measure experimentally in fixed tissues. Thus alternate approaches to the evaluation of hypoxia may be more accurate than IHC evaluation of select hypoxia-related genes [19] .
To conclude, this is one of the first studies examining molecular predictors of response to RT fractionation schedules in breast cancer. This was a large RCT of node-negative breast cancer patients treated uniformly and closely followed prospectively for over 12 years. The biomarker component of the study was applied retrospectively to the tissue samples acquired, but the biomarkers (grade, molecular subtype and hypoxia) were focused and supported by a sound scientific rationale with an analysis plan devised before the conduction of the assays in keeping with the retrospective-prospective design for biomarker evaluation suggestion by Simon et al. [20] . Nevertheless, the original trial was a noninferiority study and was not adequately powered to detect differences in subgroups. Patients were treated before the availability of trastuzumab which has been shown to reduce the incidence of both local and distant recurrence. The designation of molecular subtype is based on a limited number of IHC antibodies and while this panel has been demonstrated to have the highest sensitivity and specificity, when compared with expression based genotyping the IHC subtyping is still only an approximation of the latter.
In summary, this study supports the finding that tumor molecular subtype is an independent predictor of LR in early stage breast cancers treated with BCS and RT. However, neither tumor grade nor subtype is predictive of response to hypofractionated RT, suggesting that tumors of all grades and molecular subtypes may be effectively treated with this RT fractionation schedule. 
